CA2943373C - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders - Google Patents

2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders Download PDF

Info

Publication number
CA2943373C
CA2943373C CA2943373A CA2943373A CA2943373C CA 2943373 C CA2943373 C CA 2943373C CA 2943373 A CA2943373 A CA 2943373A CA 2943373 A CA2943373 A CA 2943373A CA 2943373 C CA2943373 C CA 2943373C
Authority
CA
Canada
Prior art keywords
compound
disease
compounds
mixture
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2943373A
Other languages
English (en)
French (fr)
Other versions
CA2943373A1 (en
Inventor
Ana Maria Garcia Collazo
David John Augustus ECKLAND
Maria Pilar Pizcueta Lalanza
Marc Martinell Pedemonte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of CA2943373A1 publication Critical patent/CA2943373A1/en
Application granted granted Critical
Publication of CA2943373C publication Critical patent/CA2943373C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2943373A 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders Active CA2943373C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382130.4 2014-04-02
EP14382130 2014-04-02
PCT/EP2015/057224 WO2015150476A1 (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Publications (2)

Publication Number Publication Date
CA2943373A1 CA2943373A1 (en) 2015-10-08
CA2943373C true CA2943373C (en) 2023-01-10

Family

ID=50513194

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2943373A Active CA2943373C (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Country Status (24)

Country Link
US (3) US9782395B2 (enExample)
EP (2) EP3388064B1 (enExample)
JP (2) JP6745726B2 (enExample)
KR (1) KR102418167B1 (enExample)
CN (1) CN106470991B (enExample)
AU (1) AU2015239112C1 (enExample)
CA (1) CA2943373C (enExample)
CL (1) CL2016002508A1 (enExample)
CY (2) CY1120454T1 (enExample)
DK (2) DK3388064T3 (enExample)
EA (2) EA202091120A3 (enExample)
ES (2) ES2678046T3 (enExample)
HR (2) HRP20180983T1 (enExample)
HU (2) HUE039555T2 (enExample)
IL (1) IL248037B (enExample)
LT (2) LT3388064T (enExample)
MX (1) MX373234B (enExample)
NZ (1) NZ725492A (enExample)
PL (2) PL3388064T3 (enExample)
PT (2) PT3388064T (enExample)
SG (1) SG11201608218QA (enExample)
SI (2) SI3388064T1 (enExample)
WO (1) WO2015150476A1 (enExample)
ZA (1) ZA201607286B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
ES2678046T3 (es) * 2014-04-02 2018-08-08 Minoryx Therapeutics S.L. Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central
LT3548026T (lt) * 2016-12-01 2021-05-25 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dionas nealkoholinio kepenų suriebėjimo gydymui
EP3559010B1 (en) * 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
PL3801515T3 (pl) 2018-06-06 2025-07-14 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych
WO2019234689A1 (en) * 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
US20210228558A1 (en) 2018-06-06 2021-07-29 Minoryx Therapeutics S.L. Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
KR20230035522A (ko) 2020-04-30 2023-03-14 미노릭스 테라퓨틱스 에스.엘. 폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
AU2024268104A1 (en) 2023-05-09 2025-11-27 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
WO1993022445A1 (en) * 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20050107450A1 (en) 2001-12-21 2005-05-19 Brown Kathleen K. Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
WO2005016339A1 (en) * 2003-07-24 2005-02-24 Case Western Reserve University Methods for the treatment of parkinson's disease
MX356584B (es) * 2006-03-16 2018-06-05 Metabolic Solutions Dev Co Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
MX2012006730A (es) * 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) * 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
US8969581B2 (en) * 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
ES2678046T3 (es) * 2014-04-02 2018-08-08 Minoryx Therapeutics S.L. Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central

Also Published As

Publication number Publication date
CN106470991A (zh) 2017-03-01
EA201691997A1 (ru) 2017-02-28
MX2016012687A (es) 2017-04-27
JP2017511339A (ja) 2017-04-20
CY1124088T1 (el) 2022-05-27
EA035866B1 (ru) 2020-08-21
KR20160145639A (ko) 2016-12-20
ES2872335T3 (es) 2021-11-02
ZA201607286B (en) 2021-07-28
EP3388064A1 (en) 2018-10-17
EA202091120A3 (ru) 2020-12-30
LT3388064T (lt) 2021-05-25
US20180133202A1 (en) 2018-05-17
US9782395B2 (en) 2017-10-10
DK3125888T3 (en) 2018-06-25
AU2015239112A1 (en) 2016-11-10
PT3125888T (pt) 2018-07-20
EP3125888A1 (en) 2017-02-08
PL3125888T3 (pl) 2018-09-28
ES2678046T3 (es) 2018-08-08
EA202091120A2 (ru) 2020-08-31
CA2943373A1 (en) 2015-10-08
NZ725492A (en) 2023-06-30
HUE055351T2 (hu) 2022-05-28
IL248037A0 (en) 2016-11-30
SG11201608218QA (en) 2016-10-28
AU2015239112C1 (en) 2020-08-20
US10179126B2 (en) 2019-01-15
US20190255032A1 (en) 2019-08-22
PT3388064T (pt) 2021-05-14
EP3125888B1 (en) 2018-05-23
SI3388064T1 (sl) 2021-08-31
BR112016022974A2 (pt) 2017-12-26
CY1120454T1 (el) 2019-07-10
AU2015239112B2 (en) 2020-05-07
MX373234B (es) 2020-05-08
PL3388064T3 (pl) 2021-07-19
JP2020117539A (ja) 2020-08-06
US20160235729A1 (en) 2016-08-18
SI3125888T1 (en) 2018-08-31
KR102418167B1 (ko) 2022-07-08
WO2015150476A1 (en) 2015-10-08
HUE039555T2 (hu) 2019-01-28
HRP20180983T1 (hr) 2018-08-10
CL2016002508A1 (es) 2017-04-21
JP6745726B2 (ja) 2020-08-26
HRP20210518T1 (hr) 2021-05-14
IL248037B (en) 2020-09-30
EP3388064B1 (en) 2021-03-10
CN106470991B (zh) 2020-07-31
LT3125888T (lt) 2018-07-10
DK3388064T3 (da) 2021-04-19

Similar Documents

Publication Publication Date Title
CA2943373C (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
EP3506894B1 (en) Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
JP2021147322A (ja) ステロイド系化合物及びその医薬用途
EP4363419A1 (en) Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
US20240010620A1 (en) Arylazabicyclo[2.1.1]hexylmethanols derivatives and medical uses thereof
CN115916337B (zh) 卤代烯丙基胺双胺氧化酶抑制剂
US9527852B2 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
CA3102584A1 (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
US20170298090A1 (en) Modulators of ROR-gamma Receptors, Composition and Use Thereof
HK1261676B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1261676A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233953B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233953A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233640A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1233640B (zh) 在中枢神经系统障碍治疗中的2，4-噻唑烷二酮衍生物
CN104822647B (zh) 四氢异葎草酮的衍生物，制造和使用方法
EA042526B1 (ru) Производные 2,4-тиазолидиндиона в лечении расстройств центральной нервной системы
BR112016022974B1 (pt) Uso de um composto ou mistura dos compostos derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso central

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200331

EEER Examination request

Effective date: 20200331

EEER Examination request

Effective date: 20200331

EEER Examination request

Effective date: 20200331

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317